Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 25 tags : Trial save search
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
Published: 2021-10-25 (Crawled : 00:00) - biospace.com/
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 0.22%
H: 2.43%
C: 1.48%
disease phase 1 results molecular trial phase 2 phase 3
New Software Clears Clinical Trial
Published: 2021-10-25 (Crawled : 17:00) - intricon.com
IIN | $24.24 0.04% 0.04%
|
Health Technology
|
| O: 0.0%
H: 2.39%
C: 0.46%
software trial
Clinical Trial Manager, Trial Operations Supply Management
Published: 2021-10-25 (Crawled : 16:00) - atyrpharma.com
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: -1.29%
H: 3.21%
C: 2.38%
trial
Pandemic-Driven Changes in Pharma Here to Stay as New Clinical Trial Models Take Hold
Published: 2021-10-25 (Crawled : 14:00) - biospace.com/
ORCL | $114.88 -0.97% 0.01% 8.2M
|
Technology Services
|
| O: 0.19%
H: 0.52%
C: -0.56%
trial pharma
Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
Published: 2021-10-25 (Crawled : 14:00) - biospace.com/
FNCH | $2.205 -6.57% -7.03% 30K
|
Professional, Scientific, and T...
|
| O: -0.9%
H: 7.94%
C: 7.86%
positive trial
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-10-25 (Crawled : 14:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.49%
H: 0.6%
C: -5.91%
disease alzheimer dementia clinical trials parkinson trials trial conference alzheimer’s alzheimer's disease alzheimer's
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.98%
C: -0.58%
injection trial
DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
DICE | $47.55 0.06% 0.08% 0
|
|
| O: 2.14%
H: 0.0%
C: -1.13%
psoriasis treatment phase 1 trial phase 2 phase 3
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
phase 1 positive topline trial phase 2 phase 3
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
Published: 2021-10-25 (Crawled : 13:00) - aquestive.com
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: -0.27%
lung cancer collaboration cancer trial initiated keytruda
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions
Published: 2021-10-25 (Crawled : 13:00) - globenewswire.com
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
Published: 2021-10-25 (Crawled : 12:15) - appliedtherapeutics.com
APLT A | $4.4 -7.17% -7.73% 2.9M
|
Health Technology
|
| O: -11.84%
H: 14.97%
C: 12.25%
trial biomarkers
CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
CASI | $2.24 -1.36% 10K
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: -2.18%
commercialization trials trial
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.1%
H: 0.86%
C: 0.78%
treatment positive results trials phase 3 trial hiv topline injection infections
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: -2.17%
H: 1.85%
C: -0.37%
phase 3 trial enroll
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
Published: 2021-10-25 (Crawled : 11:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.08%
H: 0.77%
C: 0.16%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: -0.88%
H: 1.92%
C: 0.88%
solid tumors collaboration trial cel
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Published: 2021-10-25 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.89%
H: 0.26%
C: -0.12%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.38%
H: 0.88%
C: 0.44%
disease phase 3 trial dupixent
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.